Related Experiment Videos
Beta 2-microglobulin expression in human embryonal neuroblastoma reflects its developmental regulation
M J Cooper1, G M Hutchins, R J Mennie
1Molecular Genetics Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Cancer Research
|June 15, 1990
Summary
Neuroblastoma tumors show beta 2-microglobulin (B2M) expression linked to cell differentiation, not N-myc oncogene levels. This suggests neuroblastomas arise from arrested development of adrenal cells.
Area of Science:
- Oncology
- Immunology
- Developmental Biology
Background:
- Class I Major Histocompatibility Complex (MHC) antigen expression is implicated in neuroblastoma oncogenicity.
- N-myc amplification correlates with rapid tumor progression and can decrease Class I MHC antigen expression.
Purpose of the Study:
- To investigate the relationship between N-myc expression, Class I MHC antigen levels, and tumor differentiation in neuroblastoma.
- To determine if beta 2-microglobulin (B2M) expression in neuroblastoma is associated with N-myc levels or differentiation stage.
Main Methods:
- Quantification of N-myc mRNA and Class I MHC cell surface antigens in 24 human neuroblastoma cell lines.
- Examination of B2M expression during human adrenal medulla development.
- Morphological and immunological assessment of B2M expression in differentiated neuroblastoma tumor cells.
Main Results:
- N-myc expression was not consistently associated with low beta 2-microglobulin (B2M) and Class I MHC antigen levels.
- B2M expression was identified as a marker of differentiated adrenal medullary cells, appearing late in development.
- B2M was found to be expressed in differentiated neuroblastoma tumor cells.
Conclusions:
- B2M expression in neuroblastoma is linked to the tumor cell's differentiation stage, independent of N-myc expression.
- Neuroblastomas may represent arrested differentiation of adrenal neuroblasts at various developmental stages.